INVENTOR SEARCH

=> fil capl; d que nos l19
FILE 'CAPLUS' ENTERED AT 12:23:45 ON 14 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 14 Jan 2008 VOL 148 ISS 3
FILE LAST UPDATED: 13 Jan 2008 (20080113/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L1	1	SEA FILE=CAPLUS ABB=ON US2005-524989/AP
L9		STR
L12	614	SEA FILE=REGISTRY SSS FUL L9
L13	12	SEA FILE=CAPLUS ABB=ON L12
L14	1263	SEA FILE=CAPLUS ABB=ON ANDRES GIL J?/AU OR ANDRES J?/AU OR GIL J?/AU
L15	52	SEA FILE=CAPLUS ABB=ON ALCAZAR VACA M?/AU OR ALCAZAR M?/AU OR VACA M?/AU
L16	152	SEA FILE=CAPLUS ABB=ON MATESANZ BALLESTEROS M?/AU OR MATESANZ M?/AU OR BALLESTEROS M?/AU
L17	258	SEA FILE=CAPLUS ABB=ON BAKKER M?/AU
L18	85	SEA FILE=CAPLUS ABB=ON MEGENS A?/AU
L19	10	SEA FILE=CAPLUS ABB=ON (L1 OR L14 OR L15 OR L16 OR L17 OR L18) AND L13

=> d ibib abs hitstr l19 1-10

L19 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:474148 CAPLUS Full-text
DOCUMENT NUMBER: 146:492615
TITLE: Tricyclic isoxazolines: Identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and α2-adrenoceptor antagonism
AUTHOR(S): Andrés, J. Ignacio; Alcazar, Jesus; Alonso, Jose M.; Alvarez, Rosa M.; Bakker, Margot H. ; Biesmans, Ilse; Cid, Jose M.; De Lucas, Ana I.; Drinkenburg, Wilhelmus; Fernandez, Javier; Font, Luis M.; Iturrino, Laura; Langlois, Xavier; Lenaerts, Ilse; Martinez, Sonia; Megens, Anton A.; Pastor,

Joaquin; Pullan, Shirley; Steckler, Thomas
CORPORATE SOURCE: Research & Early Development-EU, CNS-Psychiatry, Division of Janssen-Cilag, Medicinal Chemistry Department, Johnson & Johnson Pharmaceutical Research & Development, Toledo, 45007, Spain
SOURCE: Bioorganic & Medicinal Chemistry (2007), 15(11), 3649-3660
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 146:492615
GI



AB In previous articles we have described the discovery of a new series of tricyclic isoxazolines combining central serotonin (5-HT) reuptake inhibition with α2-adrenoceptor antagonistic activity. We report now on the synthesis, the in vitro binding potency and the primary in vivo activity of six enantiomers within this series, one of which was selected for further pharmacol. evaluation and assigned as R226161 (I). Some addnl. in vivo studies in rats are described with this compound, which proved to be centrally and orally active as a combined 5-HT reuptake inhibitor and α2-adrenoceptor antagonist.

IT 452313-46-1P 452313-65-4P 452313-68-7P
452313-71-2P 452314-01-1P 452318-73-9P
452318-75-1P 722545-47-3P 936362-34-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Tricyclic isoxazolines: Identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and α2-adrenoceptor antagonism)

RN 452313-46-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-65-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452313-68-7 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-71-2 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aS)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452314-01-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-73-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-75-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 722545-47-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 936362-34-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



IT 452313-36-9 452318-26-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Tricyclic isoxazolines: Identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and α2-adrenoceptor antagonism)
RN 452313-36-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX

NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-26-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:505909 CAPLUS Full-text
DOCUMENT NUMBER: 145:95782
TITLE: Synthesis of 7-amino-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazole derivatives displaying combined α2-adrenoceptor antagonistic and 5-HT reuptake inhibiting activities
AUTHOR(S): Andres, J. Ignacio; Alcazar, Jesus; Alonso, Jose M.; De Lucas, Ana I.; Iturrino, Laura; Biesmans, Ilse; Megens, Anton A.
CORPORATE SOURCE: Medicinal Chemistry Department, Division of Janssen-Cilag, Johnson & Johnson Pharmaceutical Research and Development, Toledo, 45007, Spain
SOURCE: Bioorganic & Medicinal Chemistry (2006), 14(13), 4361-4372
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 145:95782

AB Following a program searching for dual 5-HT reuptake inhibitors and α2-adrenoceptor antagonists started at Johnson & Johnson Pharmaceutical Research & Development, we now report on the synthesis of a series of 7-amino-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazole derivs., some of which proved to be the most potent α2-adrenoceptor blockers within this chemical class of tricyclic isoxazolines, while keeping potent 5-HT reuptake inhibiting activity.

IT 612074-52-9P 612074-56-3P 612074-57-4P
612074-68-7P 612074-81-4P 612074-88-1P
612074-89-2P 612074-90-5P 612074-92-7P
612074-93-8P 612074-94-9P 612074-95-0P
612074-98-3P 612074-99-4P 612075-02-2P
612075-03-3P 612075-07-7P 612075-09-9P
612075-10-2P 612075-11-3P 612075-12-4P
612075-13-5P 612075-15-7P 612075-88-4P
776707-27-2P 895169-63-8P 895169-64-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(benzopyranoisoxazole derivs. displaying combined α2-adrenoceptor antagonistic and 5-HT reuptake inhibiting activities)

RN 612074-52-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-N-(phenylmethyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-56-3 CAPLUS
CN Acetamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-57-4 CAPLUS
CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(3,4-

dimethoxyphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-68-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-ethyl-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-81-4 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-88-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-N-phenyl-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-89-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-N-phenyl-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-90-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-(4-fluorophenyl)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-92-7 CAPLUS
CN Benzonitrile, 3-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-93-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-(2-methylphenyl)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-94-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-(3,4-dimethylphenyl)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-95-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-N-(phenylmethyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-98-3 CAPLUS
CN Propanamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2,2-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-99-4 CAPLUS
CN Cyclopropanecarboxamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-02-2 CAPLUS
CN 2-Propenamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-03-3 CAPLUS
CN Benzamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-07-7 CAPLUS
CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-ethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-09-9 CAPLUS
CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(1,1-dimethylethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-10-2 CAPLUS
CN Urea, N-cyclohexyl-N'-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-11-3 CAPLUS
CN Glycine, N-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]carbonyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-12-4 CAPLUS
CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-phenyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-13-5 CAPLUS
CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(3-fluorophenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-15-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-88-4 CAPLUS
CN 1,2-Ethanediamine, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N,N',N'-trimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 770707-27-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 895169-63-8 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 895169-64-9 CAPLUS
CN Ethanol, 2-[[(3S,3aR)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 452318-26-2 452319-41-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzopyranoisoxazole derivs. displaying combined α2-adrenoceptor antagonistic and 5-HT reuptake inhibiting activities)
RN 452318-26-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-41-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 452319-29-8P 612074-55-2P 895169-62-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(benzopyranoisoxazole derivs. displaying combined α2-adrenoceptor antagonistic and 5-HT reuptake inhibiting activities)
RN 452319-29-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-fluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-55-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 895169-62-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-bromo-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:920735 CAPLUS Full-text
DOCUMENT NUMBER: 142:219240
TITLE: Discovery of a New Series of Centrally Active Tricyclic Isoxazoles Combining Serotonin (5-HT)

Reuptake Inhibition with α2-Adrenoceptor Blocking Activity

AUTHOR(S): Andres, J. Ignacio; Alcazar, Jesus; Alonso, Jose M.; Alvarez, Rosa M.; Bakker, Margot H. ; Biesmans, Ilse; Cid, Jose M.; De Lucas, Ana I.; Fernandez, Javier; Font, Luis M.; Hens, Koen A.; Iturrino, Laura; Lenaerts, Ilse; Martinez, Sonia; Megens, Anton A.; Pastor, Joaquin; Vermote, Patrick C. M.; Steckler, Thomas

CORPORATE SOURCE: Johnson Johnson Pharmaceutical Research Development Division of Janssen-Cilag Medicinal Chemistry dept., Jarama s/n, Toledo, 45007, Spain

SOURCE: Journal of Medicinal Chemistry (2005), 48(6), 2054-2071
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:219240

AB The synthesis and pharmacol. of a new series of 3-piperazinylmethyl-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles that combine central serotonin (5-HT) reuptake inhibition with α2-adrenoceptor blocking activity is described as potential antidepressants. Four compds. were selected for further evaluation, and the combination of both activities was found to be stereoselective, residing mainly in one enantiomer. Reversal of the loss of righting induced by the α2-agonist medetomidine in rats confirmed the α2-adrenoceptor blocking activity in vivo and also demonstrated CNS penetration. Antagonism of p-chloroamphetamine (pCA)-induced excitation as well as blockade of the neuronal 5-HT depletion induced by p-CA administration in rats confirmed their ability to block the central 5-HTT, even after oral administration. Replacement of the oxygen atom at the 5-position of the tricyclic scaffold by a nitrogen or a carbon atom, as well as O-substitution at position 7, led also to active compds., both in vitro and in vivo.

IT 452313-54-1P 452318-20-6P 452318-95-5P 608146-13-6P

RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of centrally active tricyclic isoxazoles combining 5-HT reuptake inhibition with α2-adrenoceptor blocking activity)

RN 452313-54-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-20-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-95-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 608146-13-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



IT 452319-41-4
RL: PAC (Pharmacological activity); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)

(preparation of centrally active tricyclic isoxazoles combining 5-HT reuptake inhibition with α2-adrenoceptor blocking activity)

RN 452319-41-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



IT 452313-65-4P 452319-33-4P 452320-36-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation of centrally active tricyclic isoxazoles combining 5-HT reuptake inhibition with α2-adrenoceptor blocking activity)

RN 452313-65-4 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 452319-33-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 452320-36-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 452312-36-9P 452313-59-6P 452313-77-8P
452318-26-2P 452318-93-3P 452319-43-6P
452319-55-0P 452319-57-2P 452319-59-4P
452319-61-8P 452319-63-0P 452319-65-2P
452319-67-4P 452319-69-6P 452319-71-0P
452320-40-0P 452320-52-4P 452320-54-6P
452320-60-4P 452320-62-6P 452320-64-8P
452320-66-0P 452320-70-6P 452321-33-4P
452321-35-6P 452321-37-8P 452321-39-0P
452321-41-4P 789484-08-8P 815632-62-3P
815632-63-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of centrally active tricyclic isoxazoles combining 5-HT reuptake inhibition with α2-adrenoceptor blocking activity)
RN 452313-36-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452313-59-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452313-77-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452318-26-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-93-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 452319-43-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-(2-methoxyethoxy)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-55-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-57-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, propanoate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-59-4 CAPLUS
CN Acetic acid, methoxy-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-61-8 CAPLUS
CN Cyclopropanecarboxylic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-63-0 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-65-2 CAPLUS
CN 2-Propenoic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-67-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(cyclopentyloxy)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-69-6 CAPLUS
CN 4-Pyridinecarboxylic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-71-0 CAPLUS
CN Ethanamine, 2-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]-N,N-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-40-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-52-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-5-methyl-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-54-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-5-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-60-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-5-(trifluoroacetyl)-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-62-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 5-acetyl-3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-64-8 CAPLUS
CN Isoxazolo[4,3-c]quinoline-5(3H)-carboxylic acid, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, ethyl ester, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-66-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline-5(3H)-carboxamide, N-ethyl-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-70-6 CAPLUS
CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-33-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(4-chlorophenyl)methyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452321-35-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[2-(4-fluorophenoxy)ethyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452321-37-8 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-39-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452321-41-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(6-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 789484-08-8 CAPLUS
CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 815632-62-3 CAPLUS
CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 815632-63-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-[2-(2-ethoxyethoxy)ethoxy]-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 452313-56-3P 452318-24-0P 452318-97-7P
608146-12-9P
RL: PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)
(preparation of centrally active tricyclic isoxazoles combining 5-HT reuptake inhibition with α2-adrenoceptor blocking activity)
RN 452313-56-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-24-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)-(9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-97-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 608146-12-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:362586 CAPLUS Full-text
DOCUMENT NUMBER: 141:123602
TITLE: Synthesis of 3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, displaying combined 5-HT uptake inhibiting and α2-adrenoceptor antagonistic activities. Part 2: Further exploration on the cinnamyl moiety
AUTHOR(S): Pastor, Joaquin; Alcazar, Jesus; Alvarez, Rosa M.; Andres, J. Ignacio; Cid, Jose M.; De Lucas, Ana I.; Diaz, Adolfo; Fernandez, Javier; Font, Luis M.; Iturrino, Laura; Lafuente, Celia; Martinez, Sonia; Bakker, Margot H.; Biesmans, Ilse; Heylen, Lieve I.; Megens, Anton A.
CORPORATE SOURCE: Division of Janssen-Cilag, Medicinal Chemistry Department, Johnson & Johnson Pharmaceutical Research & Development, Toledo, 45007, Spain
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(11), 2917-2922
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:123602

AB The synthesis of a series of 3-(4-cinnamyl-1-piperazinylmethyl)-3a,4- dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, as novel dual 5-HT reuptake inhibitors and α2-adrenoceptor antagonists is reported.

IT 452313-36-9P 452313-85-8P 452316-95-9P
452316-97-1P 452318-26-2P 452318-71-7P
452318-73-9P 452318-77-3P 452318-83-1P
452318-87-5P 452318-93-3P 452319-01-6P
452319-03-8P 452319-07-2P 452319-09-4P
452320-98-8P 452321-14-1P 452321-21-0P
452321-29-8P 452321-31-2P 722545-47-3P
722545-48-4P 722545-55-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of 3-(4-cinnamyl-1-piperazinylmethyl)-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles as combined 5-HT uptake inhibitors and α2-adrenoceptor antagonists)

RN 452313-36-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452313-85-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(3-thienyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452316-95-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452316-97-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 452318-26-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-71-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-73-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-77-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-83-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,5-difluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-87-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,3-difluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-93-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-01-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-thienyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-03-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(2-thienyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-07-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-furanyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-09-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(3-pyridinyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-98-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-14-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-21-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,4-difluorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-29-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-thienyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-31-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-furanyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 722545-47-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 722545-48-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-chlorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 722545-55-3 CAPLUS
CN Phenol, 4-[(1E)-3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-methyl-1-propenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 722545-57-5P 722545-58-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of 3-(4-cinnamyl-1-piperazinylmethyl)-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles as combined 5-HT uptake inhibitors and α2-adrenoceptor antagonists)
RN 722545-57-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-pentenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 722545-58-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(3,3-diphenyl-2-propenyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:182890 CAPLUS Full-text
DOCUMENT NUMBER: 140:217631
TITLE: Preparation of fused heterocyclic isoxazoline derivatives as anti-depressants
INVENTOR(S): Andres-Gil, Jose Ignacio; Alcazar-Vaca, Manuel Jesus; Bartolome-Nebreda, Jose Manuel; Fernandez-Gadea, Francisco Javier; Bakker, Margaretha Henrica Maria; Megens, Antonius Adrianus Hendrikus Petrus
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018483	A1	20040304	WO 2003-EP50377	20030813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2494557	A1	20040304	CA 2003-2494557	20030813
AU 2003262573	A1	20040311	AU 2003-262573	20030813
EP 1554286	A1	20050720	EP 2003-792431	20030813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1675224	A	20050928	CN 2003-819462	20030813
JP 2005538144	T	20051215	JP 2004-530272	20030813
US 2006116378	A1	20060601	US 2005-524123	20050210
PRIORITY APPLN. INFO.:			EP 2002-78373 A	20020815
			WO 2003-EP50377 W	20030813

OTHER SOURCE(S): MARPAT 140:217631

GI



I

II

AB The invention concerns fused heterocyclic isoxazoline derivs. of formula I [X = CH2, (substituted) NH, S, O; Y = (substituted) heterocyclic ring; Z = (substituted) piperazine, piperidinemethylamine, etc.; R = alkylene-aromatic ring, etc.; m = 1-4], the pharmaceutically acceptable salts thereof, the stereochem. isomeric forms thereof and the N-oxide form thereof, more in particular, tetrahydropyranoisoxazole, hexahydroisoxazolopyridine, tetrahydrothiopyrano isoxazole and hexahydrobenzoisoxazole derivs. fused to a heterocyclic ring system via the 6-membered ring of the bicyclic moiety, as well as processes for their preparation, pharmaceutical compns. comprising them and their use as a medicine, in particular for treating depression, anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders including anorexia nervosa and bulimia. The compds. have been shown to have selective serotonin (5-HT) reuptake inhibitor activity as well as α2-adrenoceptor antagonist activity. Thus, II was prepared, and had pIC50 if 8.4 in 5-HT transporter binding experiment

IT 666233-82-5P

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(preparation of fused heterocyclic isoxazoline derivs. as antidepressants)

RN 666233-82-5 CAPLUS

CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole-7-ethanol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 666233-90-5P 666233-91-6P

RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of fused heterocyclic isoxazoline derivs. as antidepressants)

RN 666233-90-5 CAPLUS
CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole-7-ethanol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3S,3aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 666233-91-6 CAPLUS
CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole-7-ethanol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 666233-75-6P 666233-84-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of fused heterocyclic isoxazoline derivs. as antidepressants)
RN 666233-75-6 CAPLUS
CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 666233-84-7 CAPLUS
CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole-7-acetic acid, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, methyl ester, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



IT 666233-76-7P 666233-77-8P 666233-78-9P
666233-79-0P 666233-80-3P 666233-81-4P
666233-83-6P 666233-85-8P 666233-86-9P
666233-87-0P 666233-88-1P 666233-89-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fused heterocyclic isoxazoline derivs. as antidepressants)

RN 666233-76-7 CAPLUS
CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 666233-77-8 CAPLUS
CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 666233-78-9 CAPLUS
CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole, 3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 666233-79-0 CAPLUS
CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole, 3-[[4-[(4-chlorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 666233-80-3 CAPLUS
CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 666233-81-4 CAPLUS
CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole, 3a,4-dihydro-7-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 666233-83-6 CAPLUS
CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole, 3a,4-dihydro-7-[(2-methoxyethoxy)methyl]-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 666233-85-8 CAPLUS
CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole, 7-acetyl-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 666233-86-9 CAPLUS
CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole, 7-(cyclopropylcarbonyl)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 666233-87-0 CAPLUS
CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole-7-carboxylic acid, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, methyl ester, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 666233-88-1 CAPLUS
CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole, 3a,4-dihydro-7-(methoxyacetyl)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 666233-89-2 CAPLUS
CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole, 7-ethyl-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:182889 CAPLUS Full-text
DOCUMENT NUMBER: 140:235700
TITLE: Preparation of chromenoisoxazole derivatives and their use as anti-depressants
INVENTOR(S): Andres-Gil, Jose Ignacio; Alcazar-Vaca, Manuel Jesus; Matesanz-Ballesteros, Maria Encarnacion; Bakker, Margaretha Henrica Maria; Megens, Antonius Adrianus Hendrikus Petrus
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.

SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018482	A2	20040304	WO 2003-EP9532	20030819
WO 2004018482	A3	20040401		
WO 2004018482	A8	20050324		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2495058	A1	20040304	CA 2003-2495058	20030819
AU 2003271567	A1	20040311	AU 2003-271567	20030819
EP 1532155	A2	20050525	EP 2003-753363	20030819
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1675223	A	20050928	CN 2003-819862	20030819
JP 2005538143	T	20051215	JP 2004-530256	20030819
US 2006122167	A1	20060608	US 2005-524989	20050218 <--
PRIORITY APPLN. INFO.:			EP 2002-78844 A	20020821
			WO 2003-EP9532 W	20030819

OTHER SOURCE(S): MARPAT 140:235700
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = CH2, NR7, S or O; R7 = H, alkyl, (un)substituted- aryl, -arylalkyl; R1, R2, R14, R15 = independently H, halo, OH, alkyloxy, CN, etc.; m = 1-4; R3 = (un)substituted aromatic homocyclic or heterocyclic ring; R8 = independently OH, amino, nitro, CN, halo, or alkyl; n = 0-5; R9 = H, alkyl, or formyl], a process for their preparation, pharmaceutical compns. comprising them and their use as a medicine, in particular for the treatment of depression, anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders is disclosed. Thus, e.g., II, was prepared by substitution of 6-bromo-7,8-dimethoxy-3-[4-(2-methyl-3- phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole (preparation given) with N-methylpiperazine. The compds. according to the invention have surprisingly been shown to have a serotonin (5-HT) reuptake inhibitor activity in combination with addnl. α2-adrenoceptor antagonist activity and show a strong anti-depressant activity without being sedative. I produced an inhibition at least at the hα2A site (but often at the hα2B and hα2C sites) and simultaneously at the 5-HT transporter site of more than 50 % (pIC50) at a test concentration ranging between 10-6 M and 10-9 M in a concentration-dependent manner. The invention also relates to novel combination of isoxazoline derivs. according to the invention with one or more other compds.

selected from the group of antidepressants, anxiolytics, anti-psychotics and anti-Parkinson's disease drugs to improve efficacy and/or onset of action.

IT 667454-35-5P 667454-39-9P 667454-52-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of chromenoisoxazole derivs. as antidepressants)

RN 667454-35-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 6-bromo-3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 667454-39-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-6-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 667454-52-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-6-iodo-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 667454-36-6P 667454-37-7P 667454-38-8P
667454-40-2P 667454-41-3P 667454-42-4P
667454-43-5P 667454-44-6P 667454-45-7P
667454-46-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of chromenoisoxazole derivs. as antidepressants)
RN 667454-36-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 6-(4-bromo-1-piperazinyl)-3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 667454-37-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-6-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 667454-38-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-6-carboxylic acid, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, ethyl ester, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 667454-40-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-6-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 667454-41-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-6-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-N-4-pyridinyl-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 667454-42-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-9-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX

NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 667454-43-5 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-6-yl]oxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 667454-44-6 CAPLUS
CN Acetic acid, methoxy-, 2-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-6-yl]oxy]ethyl ester, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 667454-45-7 CAPLUS
CN Acetic acid, methoxy-, 2-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-6-yl]oxy]ethyl ester, rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 667454-46-8 CAPLUS
CN Carbamic acid, ethyl-, 2-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-9-yl]oxy]ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



L19 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:162696 CAPLUS Full-text
DOCUMENT NUMBER: 140:217662
TITLE: Preparation of piperazinylalkylchromenoisoxazolines as antidepressants.
INVENTOR(S): Andres-gil, Jose Ignacio; Bartolome-nebreda, Jose Manuel; Alvarez-escobar, Rosa Maria; Bakker, Margaretha Henrica Maria; Megens, Antonius Adrianus Hendrikus Petrus
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004016621	A1	20040226	WO 2003-EP50374	20030812
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

CA 2494235	A1	20040226	CA 2003-2494235	20030812
AU 2003262571	A1	20040303	AU 2003-262571	20030812
EP 1537124	A1	20050608	EP 2003-787817	20030812
EP 1537124	B1	20070801		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1675222	A	20050928	CN 2003-819483	20030812
JP 2005537304	T	20051208	JP 2004-528523	20030812
AT 368669	T	20070815	AT 2003-787817	20030812
US 2005256119	A1	20051117	US 2005-524197	20050210
PRIORITY APPLN. INFO.:			EP 2002-78322 A	20020812
			WO 2003-EP50374 W	20030812
OTHER SOURCE(S):	MARPAT 140:217662			

GI



I



II

AB Title compds. [I; X = CH2, NR7, S, O; R7 = H, alkyl aryl, aralkyl, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl; R1, R2 = H, halo, OH, OSO2H, OSO2Me, alkoxy, alkyl, aryl, heterocyclyl, etc.; R1R2 = (CH2)4, CH:CHCH2CH2, CH:CHCH:CH, etc.; Pir = (substituted) piperazinyl, aminomethylpiperidinyl; m = 1-4; R3 = (substituted) (unsatd.) alkylaryl, alkylheteroaryl; with provisos], were prepared Thus, title compound (II) (preparation via intramol. nitrile oxide cycloaddn. given) bound to human platelet 5-HT transporter protein with pIC50 = 7.7.

IT 452320-31-9P 663933-45-7P, 8-Methyl-3-[4-(3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-46-8P, 8-Methoxy-7-methyl-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-47-9P, [8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazol-7-yl]methanol 663933-48-0P, 7-Methoxymethyl-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-49-1P 663933-50-4P 663933-51-5P, 8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-7-phenoxymethyl-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-52-6P 663933-53-7P, 8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-7-morpholin-4-ylmethyl-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-54-8P 663933-55-9P 663933-56-0P, 3-[4-(2-Methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole-7-carbonitrile 663933-57-1P 663933-58-2P, 8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole-7-carboxylic acid ethylamide 663933-59-3P, 8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-7-phenyl-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-60-6P, 1-[5-[8-Methoxy-3-[4-(2-

methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazol-7-yl]thiophen-2-yl]ethanone 663933-61-7P 663933-62-8P 663933-63-9P 663933-65-1P 663933-66-2P 663933-68-4P 663933-69-5P 663933-70-8P 663933-71-9P 663933-72-0P 663933-74-2P 663933-76-4P 663933-77-5P 663933-78-6P 663933-79-7P 663933-80-0P 663933-81-1P 663933-89-9P 663933-90-2P 663933-91-3P 663933-92-4P 663933-93-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperazinylalkylchromenoisoxazolines as antidepressants)

RN 452320-31-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-phenyl-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 663933-45-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methyl-3-[[4-(3-phenyl-2-propenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 663933-46-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-7-methyl-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 663933-47-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanol, 3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 663933-48-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-(methoxymethyl)-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 663933-49-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-7-[[(2-methoxyethoxy)methoxy]methyl]-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 663933-50-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanol, 3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]-, acetate (ester) (9CI) (CA INDEX NAME)



RN 663933-51-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]-7-(phenoxymethyl)- (9CI) (CA INDEX NAME)



RN 663933-52-6 CAPLUS
CN Ethanol, 2-[[[3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methyl]methylamino]- (9CI) (CA INDEX NAME)



RN 663933-53-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]-7-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



RN 663933-54-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde, 3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]-, oxime (9CI) (CA INDEX NAME)



RN 663933-55-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde, 3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 663933-56-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carbonitrile, 3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 663933-57-1 CAPLUS
CN Acetamide, N-[[3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methyl]- (9CI) (CA INDEX NAME)



RN 663933-58-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxamide, N-ethyl-3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 663933-59-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]-7-phenyl- (9CI) (CA INDEX NAME)



RN 663933-60-6 CAPLUS
CN Ethanone, 1-[5-[3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2-thienyl]- (9CI) (CA INDEX NAME)



RN 663933-61-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-7-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-62-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-63-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanol, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-65-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-7-[[(2-methoxyethoxy)methoxy]methyl]-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 663933-64-0
CMF C31 H41 N3 O6

Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 663933-66-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanol, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-68-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-(phenoxymethyl)-, (3R,3aS)-rel-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 663933-67-3
CMF C33 H37 N3 O4

Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 663933-69-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-(4-morpholinylmethyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-70-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, oxime, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as described by E or Z.



RN 663933-71-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carbonitrile, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-72-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanamine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-74-2 CAPLUS
CN Acetamide, N-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methyl]-, rel-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 663933-73-1
CMF C28 H34 N4 O3

Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 663933-76-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxamide, N-ethyl-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 663933-75-3
CMF C29 H36 N4 O4

Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 663933-77-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-78-6 CAPLUS
CN Ethanol, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-

propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methyl]methylamino]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-79-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-(4-morpholinylmethyl)-, (3S,3aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 663933-80-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-(4-morpholinylmethyl)-, (3R,3aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 663933-81-1 CAPLUS
CN Ethanone, 1-[4-[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-

phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2-thienyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-89-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(cyclopropylmethyl)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-90-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-(methoxymethyl)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-91-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde, 3a,4-dihydro-3-[[4-

[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-92-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanamine, N-ethyl-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-(1-methylethyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-93-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-[(4-methyl-1-piperidinyl)methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



—Me

IT 663933-88-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of piperazinylalkylchromenoisoxazolines as antidepressants)
RN 663933-88-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-bromo-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:796712 CAPLUS Full-text
DOCUMENT NUMBER: 139:307799
TITLE: Preparation of isoxazoline derivatives as antidepressants
INVENTOR(S): Andres-Gil, Jose Ignacio; Alcazar-Vaca, Manuel Jesus; Bakker, Margaretha Henrica Maria; De Lucas Olivares, Ana Isabel
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082878	A1	20031009	WO 2003-EP3245	20030327

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2480113	A1	20031009	CA 2003-2480113		20030327
AU 2003219111	A1	20031013	AU 2003-219111		20030327
BR 2003008309	A	20041228	BR 2003-8309		20030327
EP 1492796	A1	20050105	EP 2003-714897		20030327
EP 1492796	B1	20070905			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1642960	A	20050720	CN 2003-807419		20030327
JP 2005522469	T	20050728	JP 2003-580343		20030327
NZ 536109	A	20060630	NZ 2003-536109		20030327
AT 372342	T	20070915	AT 2003-714897		20030327
MX 2004PA08626	A	20041206	MX 2004-PA8626		20040906
IN 2004DN02809	A	20050401	IN 2004-DN2809		20040921
ZA 2004007904	A	20051020	ZA 2004-7904		20040930
US 2005222125	A1	20051006	US 2004-510220		20041001
US 7265103	B2	20070904			
NO 2004004645	A	20041027	NO 2004-4645		20041027
PRIORITY APPLN. INFO.:			EP 2002-76239	A	20020402
			WO 2003-EP3245	W	20030327

OTHER SOURCE(S): MARPAT 139:307799

GI



I



II

AB The title isoxazoline derivs. having a piperazinyl subunit with general formula of I [wherein X = CH2, S, O, or (un)substituted NH; R1 and R2 = independently H, OH, CN, halo, OSO2H, OSO2Me, alkoxy, alkoxyalkoxy, alkoxyalkoxyalkoxy, tetrahydrofuranyloxy, alkylthio, (alkoxy)alkylcarboxy, pyridylcarboxy, alkylcarboxyalkoxy, alkoxycarboxy, alkenyloxy, alkenylcarboxy, alkylaminoalkoxy, dialkylaminoalkoxy, or (un)substituted NH2, with provisos; m = 1-4; A = (un)substituted piperazinyl, piperidinyl, or amino; R3 = (un)substituted aromatic (hetero)cyclyl] and pharmaceutically acceptable salts, stereoisomers, N-oxides, or prodrugs thereof are prepared as antidepressants for the treatment of depression, anxiety, and/or body weight disorders (no data). For example, the compound II •2HCl was prepared in a multi-step synthesis in moderate yield. II showed pIC50 of 8.9, 9.0, and 8.2 against human hα2A, hα2C, and 5-HT transporter receptor sites, resp.

IT 612074-52-9P 612074-55-2P 612074-58-5P
612074-59-6P 612074-62-1P 612074-63-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of isoxazoline derivs. as antidepressants)

RN 612074-52-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-N-(phenylmethyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 612074-55-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 612074-58-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 612074-59-6 CAPLUS

CN 1,2-Ethanediamine, N'-[(3R,3aR)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-

c]isoxazol-7-yl]-N,N-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-62-1 CAPLUS
CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazine, 7-acetyl-3a,4,8,9-tetrahydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-63-2 CAPLUS
CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazine, 3a,4,8,9-tetrahydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 612074-51-8P 612074-53-0P 612074-54-1P
612074-56-3P 612074-57-4P 612074-60-9P
612074-61-0P 612074-64-3P 612074-65-4P
612074-66-5P 612074-67-6P 612074-68-7P
612074-69-8P 612074-70-1P 612074-71-2P
612074-72-3P 612074-73-4P 612074-74-5P
612074-75-6P 612074-76-7P 612074-77-8P
612074-78-9P 612074-79-0P 612074-80-3P
612074-81-4P 612074-82-5P 612074-83-6P
612074-84-7P 612074-85-8P 612074-86-9P
612074-87-0P 612074-88-1P 612074-89-2P
612074-90-5P 612074-91-6P 612074-92-7P
612074-93-8P 612074-94-9P 612074-95-0P
612074-96-1P 612074-97-2P 612074-98-3P
612074-99-4P 612075-00-0P 612075-01-1P
612075-02-2P 612075-03-3P 612075-04-4P
612075-05-5P 612075-06-6P 612075-07-7P
612075-08-8P 612075-09-9P 612075-10-2P
612075-11-3P 612075-12-4P 612075-13-5P
612075-14-6P 612075-15-7P 612075-16-8P
612075-17-9P 612075-18-0P 612075-19-1P
612075-20-4P 612075-21-5P 612075-22-6P
612075-23-7P 612075-24-8P 612075-25-9P
612075-26-0P 612075-27-1P 612075-28-2P
612075-29-3P 612075-30-6P 612075-31-7P
612075-32-8P 612075-33-9P 612075-34-0P
612075-35-1P 612075-36-2P 612075-37-3P
612075-38-4P 612075-39-5P 612075-40-8P
612075-41-9P 612075-42-0P 612075-43-1P
612075-44-2P 612075-45-3P 612075-46-4P
612075-47-5P 612075-48-6P 612075-49-7P
612075-50-0P 612075-51-1P 612075-52-2P
612075-53-3P 612075-54-4P 612075-55-5P
612075-56-6P 612075-57-7P 612075-58-8P
612075-59-9P 612075-60-2P 612075-61-3P
612075-62-4P 612075-63-5P 612075-64-6P
612075-65-7P 612075-66-8P 612075-67-9P
612075-68-0P 612075-69-1P 612075-70-4P
612075-71-5P 612075-72-6P 612075-73-7P
612075-74-8P 612075-75-9P 612075-76-0P
612075-77-1P 612075-78-2P 612075-79-3P
612075-80-6P 612075-81-7P 612075-82-8P
612075-83-9P 612075-84-0P 612075-85-1P
612075-86-2P 612075-87-3P 612075-88-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of isoxazoline derivs. as antidepressants)

RN 612074-51-8 CAPLUS

CN 1,2-Ethanediamine, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N,N',N'-trimethyl-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-53-0 CAPLUS
CN Benzenesulfonamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-4-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 612074-54-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-(4-morpholinyl)-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-56-3 CAPLUS
CN Acetamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-57-4 CAPLUS
CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(3,4-dimethoxyphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-60-9 CAPLUS
CN Acetamide, N-[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-61-0 CAPLUS
CN 1,2-Ethanediamine, N-[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N,N',N'-trimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-64-3 CAPLUS
CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazine, 3a,4,8,9-tetrahydro-7-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-65-4 CAPLUS
CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazine, 3a,4,8,9-tetrahydro-7-(methoxyacetyl)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 612074-66-5 CAPLUS
CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazine-7-carboxamide, N-ethyl-3a,4,8,9-tetrahydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-67-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-methyl-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-68-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-ethyl-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-69-8 CAPLUS
CN 1,2-Ethanediamine, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N-methyl-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-70-1 CAPLUS
CN 1,2-Ethanediamine, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-methyl-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



PAGE 1-B

—NHMe

RN 612074-71-2 CAPLUS
CN 1,2-Ethanediamine, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N,N'-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

—NHMe

RN 612074-72-3 CAPLUS
CN 1,2-Ethanediamine, N-[(3R,3aS)-3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N,N',N'-trimethyl-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 HCl

PAGE 1-B

—NMe2

RN 612074-73-4 CAPLUS
CN 1,2-Ethanediamine, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N,N',N'-trimethyl-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

—NMe2

RN 612074-74-5 CAPLUS
CN 1,2-Ethanediamine, N'-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N,N-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

—NMe2

RN 612074-75-6 CAPLUS
CN 1,2-Ethanediamine, N,N-diethyl-N'-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-methyl-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

—NEt2

RN 612074-76-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-77-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612074-78-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612074-79-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612074-80-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-N-[2-(4-morpholinyl)ethyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



RN 612074-81-4 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-82-5 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-83-6 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-84-7 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-85-8 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-86-9 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-87-0 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-88-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-N-phenyl-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-89-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-N-phenyl-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-90-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-(4-fluorophenyl)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-91-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-N-(4-methoxyphenyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

OMe

RN 612074-92-7 CAPLUS

CN Benzonitrile, 3-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-93-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-(2-methylphenyl)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-94-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-(3,4-dimethylphenyl)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-95-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-N-(phenylmethyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-96-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-N-(phenylmethyl)-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 612074-97-2 CAPLUS
CN Acetamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-98-3 CAPLUS
CN Propanamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2,2-

dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-99-4 CAPLUS
CN Cyclopropanecarboxamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-00-0 CAPLUS
CN Cyclopropanecarboxamide, N-[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-01-1 CAPLUS
CN Cyclopropanecarboxamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 612075-02-2 CAPLUS
CN 2-Propenamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-03-3 CAPLUS
CN Benzamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-04-4 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 612075-05-5 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 612075-06-6 CAPLUS
CN Carbamic acid, [(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-07-7 CAPLUS
CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-ethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-08-8 CAPLUS
CN Imidodicarbonic diamide, N,N'-diethyl-2-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-09-9 CAPLUS
CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(1,1-dimethylethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-10-2 CAPLUS
CN Urea, N-cyclohexyl-N'-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-11-3 CAPLUS
CN Glycine, N-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]carbonyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-12-4 CAPLUS
CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-phenyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-13-5 CAPLUS
CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(3-fluorophenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-14-6 CAPLUS
CN Methanesulfonamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N-(methylsulfonyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-15-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-16-8 CAPLUS
CN 1-Piperazinecarboximidamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-4-(phenylmethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 612075-17-9 CAPLUS
CN 2-Azetidinone, 1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-18-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7-(1-pyrrolidinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-19-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7-(1-piperidinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-20-4 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

—OEt

RN 612075-21-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(3,4-dihydro-2(1H)-isoquinolinyl)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 612075-22-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-(4-methyl-1-piperazinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-23-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(4-methyl-1-piperazinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-24-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7-(4-methyl-1-piperazinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-25-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(4-methyl-1-piperazinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-26-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7-(4-phenyl-1-piperazinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-27-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7-[4-(phenylmethyl)-1-piperazinyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612075-28-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7-[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612075-29-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-(4-morpholinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-30-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(4-morpholinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-31-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7-(4-morpholinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-32-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(4-morpholinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 612075-33-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-34-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 612075-35-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-8-methoxy-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 612075-36-2 CAPLUS
CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazine, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4,8,9-tetrahydro-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-37-3 CAPLUS
CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4,8,9-tetrahydro-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-38-4 CAPLUS
CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazine, 3a,4,8,9-tetrahydro-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-39-5 CAPLUS
CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazine, 3a,4,8,9-tetrahydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 612075-40-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-8-amine, 3a,4-dihydro-N-(4-methoxyphenyl)-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-41-9 CAPLUS
CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazine, 3-[[4-[(4-chlorophenyl)methyl]-1-piperazinyl]methyl]-3a,4,8,9-tetrahydro-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 612075-42-0 CAPLUS
CN 2-Propenoic acid, 2-methyl-, 2-[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



RN 612075-43-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-1-pyrrolidinyl-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-44-2 CAPLUS
CN 1,2-Ethanediamine, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-45-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-(1-ethylpropyl)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-46-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-(1-methylpropyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-47-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-4-pyridinyl-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-48-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(2-methyl-1-pyrrolidinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-49-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(1-azetidinyl)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-50-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(4-methyl-1-piperidinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-51-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-(2-methylbutyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-52-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-ethyl-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-53-3 CAPLUS
CN 2-Propenamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-54-4 CAPLUS
CN 2-Azetidinone, 1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-55-5 CAPLUS
CN Cyclobutanecarboxylic acid, 2-[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612075-56-6 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612075-57-7 CAPLUS
CN 1,2-Ethanediamine, N'-(1,2-dimethylpropyl)-N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612075-58-8 CAPLUS
CN 1,2-Ethanediamine, N'-cyclobutyl-N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-59-9 CAPLUS
CN 2-Butenamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B

RN 612075-60-2 CAPLUS
CN Pentanamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-61-3 CAPLUS
CN Butanamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-62-4 CAPLUS
CN Cyclobutanecarboxamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-63-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-(2-methylpropyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-64-6 CAPLUS
CN Butanoic acid, 3,3-dimethyl-, 2-[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 612075-65-7 CAPLUS
CN 1,2-Ethanediamine, N'-(cyclopropylmethyl)-N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612075-66-8 CAPLUS
CN 2-Propanol, 1-[[2-[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]ethyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612075-67-9 CAPLUS
CN 1,2-Ethanediamine, N'-(1,1-dimethylpropyl)-N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612075-68-0 CAPLUS
CN 1,2-Ethanediamine, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N,N'-dimethyl-N'-2-propenyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612075-69-1 CAPLUS
CN 1,2-Ethanediamine, N-(1,1-dimethylethyl)-N'-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N,N'-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612075-70-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-[2-(1-azetidinyl)ethyl]-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-N-methyl-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612075-71-5 CAPLUS
CN Urea, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-phenyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-72-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-

2-propenyl]-1-piperazinyl]methyl]-7-(hexahydro-1H-azepin-1-yl)-3a,4-dihydro-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-73-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-[(2-methylcyclopropyl)methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me

RN 612075-74-8 CAPLUS
CN Carbamic acid, (1-methylpropyl)-, 2-[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 612075-75-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-[(1-methylcyclopropyl)methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-76-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-N-(1-methylethyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-77-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-(cyclopropylmethyl)-3-[[4-

[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-78-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-N-(1-methylpropyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-79-3 CAPLUS
CN 2-Propanol, 1-[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-80-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-N-pentyl-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-81-7 CAPLUS
CN 1-Propanol, 2-[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-82-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(3,6-dihydro-1(2H)-pyridinyl)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-83-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7-(1-piperazinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-84-0 CAPLUS
CN Urea, [(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-85-1 CAPLUS
CN Cyclopropanecarboxamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-86-2 CAPLUS
CN 2-Pyrrolidinone, 1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-3-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-87-3 CAPLUS
CN 1,2-Ethanediamine, N-[(3S,3aR)-3a,4-dihydro-8-methoxy-3-[[4-[[(1R,2S)-2-phenylcyclopropyl]methyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N,N',N'-trimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 612075-88-4 CAPLUS
CN 1,2-Ethanediamine, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N,N',N'-trimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 452319-29-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of isoxazoline derivs. as antidepressants)
RN 452319-29-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-fluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 452319-78-7 612075-96-4 612075-97-5
612075-98-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of isoxazoline derivs. as antidepressants)
RN 452319-78-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-bromo-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-96-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-bromo-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-97-5 CAPLUS
CN Carbamic acid, [(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-98-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-bromo-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:535065 CAPLUS Full-text
DOCUMENT NUMBER: 139:292184
TITLE: Synthesis of 3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, displaying combined 5-HT uptake inhibiting and α2-adrenoceptor antagonistic activities: a novel series of potential antidepressants
AUTHOR(S): Andres, J. Ignacio; Alcazar, Jesus; Alonso, Jose M.; Alvarez, Rosa M.; Cid, Jose M.; De Lucas, Ana I.; Fernandez, Javier; Martinez, Sonia; Nieto, Carmen; Pastor, Joaquin; Bakker, Margot H.; Biesmans, Ilse; Heylen, Lieve I.; Megens, Anton A.
CORPORATE SOURCE: Division of Janssen-Cilag, Medicinal Chemistry Department, Jarama s/n, Johnson & Johnson Pharmaceutical Research & Development, Toledo, 45007, Spain
SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(16), 2719-2725
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:292184

AB The synthesis of a series of novel 3-piperazinylmethyl-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles as novel dual 5-HT re-uptake inhibitors and α2-adrenoceptor antagonists is described. Their affinity at the three different human α2-adrenoceptor subtypes and the 5-HT transporter site is reported. The in vivo activity of the compds. was measured in two different assays: (1) inhibition of pCA-induced excitation, which evaluates the ability to block the central 5-HT transporter, and (2) inhibition of xylazine-induced loss of righting, which evaluates the ability to block central α2-adrenoceptors. Compds. thus prepared included (3R,3aS)-rel-3a,4-dihydro-3-[[4-[(2E)-3- phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazole, (3R,3aS)-rel-(-)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-3-phenyl- 2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazole, (3R,3aS)-rel-(+)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazole and derivs. thereof.

IT 452313-36-9P 452313-43-8P 452313-54-1P
452313-56-3P 452313-77-8P 452314-18-0P
452316-09-5P 452316-15-3P 452316-21-1P
452316-33-5P 452316-36-8P 452316-66-4P
452316-84-6P 452318-20-6P 452318-24-0P
452318-26-2P 452318-93-3P 452318-95-5P
452318-97-7P 452319-25-4P 452319-35-6P
452320-01-3P 608146-10-7P 608146-11-8P
608146-12-9P 608146-13-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of dihydro[1]benzopyrano[4,3-c]isoxazoles and their activity as
5-HT uptake inhibitors and α2-adrenoceptor antagonists (potential antidepressants))

RN 452313-36-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452313-43-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(6-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452313-54-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-56-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-77-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452314-18-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(phenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-09-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(benzo[b]thien-3-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-15-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-21-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-phenylethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-33-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenylpropyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-36-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(1H-inden-2-ylmethyl)-1-piperazinyl]methyl]-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-66-4 CAPLUS
CN 1-Propanone, 3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-84-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2Z)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-20-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-24-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)-(9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-26-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-93-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-95-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-97-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452319-25-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-35-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-01-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 608146-10-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(benzo[b]thien-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 608146-11-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(1-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 608146-12-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



RN 608146-13-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



IT 452321-89-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dihydro[1]benzopyrano[4,3-c]isoxazoles and their activity as
5-HT uptake inhibitors and α2-adrenoceptor antagonists (potential antidepressants))
RN 452321-89-0 CAPLUS
CN Phosphonium, [2-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]ethyl]triphenyl-, bromide, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:658130 CAPLUS Full-text
DOCUMENT NUMBER: 137:201298
TITLE: Preparation of substituted isoxazolines as anti-depressants
INVENTOR(S): Andres-Gil, Jose Ignacio; Fernandez-Gadea, Francisco Javier; Alcazar-Vaca, Manuel Jesus ; Cid-Nunez, Jose Maria; Pastor-Fernandez, Joaquin; Megens, Antonius Adrianus Hendrikus Petrus; Heylen, Godelieve Irma Christine Maria; Langlois, Xavier Jean Michel; Bakker, Margaretha Henrica Maria; Steckler, Thomas Horst Wolfgang
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 100 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066484	A1	20020829	WO 2002-EP1567	20020213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2437505	A1	20020829	CA 2002-2437505	20020213
AU 2002244717	A1	20020904	AU 2002-244717	20020213
AU 2002244717	B2	20070719		
EP 1368358	A1	20031210	EP 2002-712909	20020213
EP 1368358	B1	20060823		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300398	A	20031215	EE 2003-398	20020213
HU 2003003270	A2	20040128	HU 2003-3270	20020213
HU 2003003270	A3	20070328		
CN 1492871	A	20040428	CN 2002-805243	20020213
NZ 526741	A	20040430	NZ 2002-526741	20020213
BR 2002007433	A	20040601	BR 2002-7433	20020213
JP 2004518748	T	20040624	JP 2002-565998	20020213
JP 3953424	B2	20070808		
AT 337322	T	20060915	AT 2002-712909	20020213
ES 2271230	T3	20070416	ES 2002-2712909	20020213
TW 257392	B	20060701	TW 2002-91102853	20020220
IN 2003DN00968	A	20070525	IN 2003-DN968	20030624
BG 107984	A	20040930	BG 2003-107984	20030708
MX 2003PA07432	A	20031118	MX 2003-PA7432	20030819
NO 2003003700	A	20031021	NO 2003-3700	20030820
ZA 2003006487	A	20041122	ZA 2003-6487	20030820
US 2004122037	A1	20040624	US 2003-468555	20030821
US 7169786	B2	20070130		

PRIORITY APPLN. INFO.:
EP 2001-200611 A 20010221
EP 2001-201264 A 20010405
WO 2002-EP1567 W 20020213

OTHER SOURCE(S): MARPAT 137:201298
GI



I



II



III

AB Title compds. I [wherein X = CH2, NR7, S or O; R7 = H, (un)substituted alkyl, Ph, Ph alkyl, etc.; R1 and R2 independently = H, OH, CN, halo, OSO2H, (un)substituted Ph, phenylalkyl, alkoxy, etc.; or R1 and R2 may be taken together to form a bivalent radical selected from -CH2CH2O-, -OCH2CH2-, -OCH2O-, -CH2OCH2- and -OCH2CH2O-; m = 1-4; Y = (un)substituted piperidyl or piperazyl radical and R3 represents an (un)substituted aromatic homocyclic or heterocyclic ring system including a partially or completely hydrogenated hydrocarbon chain of maximum 6 atoms long with which the ring system is attached to the Y radical and which may contain one or more heteroatoms selected from the group of O, N and S], a process for their preparation, pharmaceutical compns. comprising them and their use as a medicine for treating anxiety disorders and disorders of body weight are disclosed. Thus, II was prepared in 60% yield by reaction of III with N-(3-phenyl-2-propenyl)-piperazine. III was prepared by substitution of Me 4-bromo-2-butenoate with 2-hydroxy-4,5-dimethoxybenzaldehyde with subsequent condensation with hydroxylamine, cyclization, reduction and sulfonation with methanesulfonyl chloride. The compds. according to the invention have surprisingly been shown to have a serotonin (5-HT) reuptake inhibitor activity in combination with addnl. α2-adrenoceptor antagonist activity and show a strong anti-depressant activity without being sedative. I produced an inhibition at the hα2A site (but often also at the hα2B and hα2C sites) and simultaneously at the 5-HT transporter site of more than 50% (pIC50) at a test concentration ranging between 10-6 M and 10-9 M in a concentration dependent manner. The invention also relates to novel combination of substituted isoxazolines derivs. having anti-depressant activity and/or anxiolytic activity and/or body weight control activity with antidepressants, anxiolytics and/or antipsychotics to improve efficacy and/or onset of action.

IT 452321-87-8P 452321-89-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)

RN 452321-87-8 CAPLUS

CN Piperazine, 1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-4-[(3,4-dihydro-2-naphthalenyl)carbonyl]-, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-89-0 CAPLUS
CN Phosphonium, [2-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]ethyl]triphenyl-, bromide, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 452323-46-5D, resin bound
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)
RN 452323-46-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(diphenylphosphino)ethyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 452313-32-5P 452313-68-7P 452313-71-2P
452313-80-3P 452313-82-5P 452316-78-8P

RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)

RN 452313-32-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



●2 HCl

RN 452313-68-7 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-71-2 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aS)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-80-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



●2 HCl

RN 452313-82-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



●2 HCl

RN 452316-78-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



●2 HCl

IT 452313-59-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(target compound; preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)
RN 452313-59-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 452313-36-9P 452313-40-5P 452313-43-8P
452313-46-1P 452313-50-7P 452313-54-1P
452313-56-3P 452313-61-0P 452313-65-4P
452313-74-5P 452313-77-8P 452313-85-8P
452313-88-1P 452313-91-6P 452313-93-8P
452313-98-3P 452314-01-1P 452314-05-5P
452314-08-8P 452314-11-3P 452314-14-6P
452314-18-0P 452314-20-4P 452314-23-7P
452314-26-0P 452314-29-3P 452314-31-7P
452314-34-0P 452314-37-3P 452314-40-8P
452314-43-1P 452314-46-4P 452314-49-7P
452314-52-2P 452314-55-5P 452314-57-7P
452314-60-2P 452314-62-4P 452314-65-7P
452314-68-0P 452314-71-5P 452314-74-8P
452314-77-1P 452314-80-6P 452314-83-9P
452314-86-2P 452314-89-5P 452314-92-0P
452314-95-3P 452314-98-6P 452315-01-4P
452315-04-7P 452315-07-0P 452315-10-5P
452315-13-8P 452315-16-1P 452315-19-4P
452315-22-9P 452315-24-1P 452315-27-4P
452315-30-9P 452315-33-2P 452315-36-5P
452315-38-7P 452315-40-1P 452315-42-3P
452315-44-5P 452315-46-7P 452315-48-9P
452315-51-4P 452315-52-5P 452315-55-8P

452315-58-1P 452315-61-6P 452315-63-8P
452315-66-1P 452315-70-7P 452315-73-0P
452315-76-3P 452315-79-6P 452315-82-1P
452315-85-4P 452315-87-6P 452315-90-1P
452315-92-3P 452315-94-5P 452315-97-8P
452316-00-6P 452316-03-9P 452316-06-2P
452316-09-5P 452316-12-0P 452316-15-3P
452316-18-6P 452316-21-1P 452316-24-4P
452316-27-7P 452316-30-2P 452316-33-5P
452316-36-8P 452316-39-1P 452316-42-6P
452316-45-9P 452316-48-2P 452316-51-7P
452316-53-9P 452316-55-1P 452316-58-4P
452316-64-2P 452316-66-4P 452316-69-7P
452316-72-2P 452316-75-5P 452316-81-3P
452316-84-6P 452316-87-9P 452316-89-1P
452316-91-5P 452316-93-7P 452316-95-9P
452316-97-1P 452316-99-3P 452317-02-1P
452317-04-3P 452317-06-5P 452317-08-7P
452317-10-1P 452317-12-3P 452317-14-5P
452317-16-7P 452317-18-9P 452317-20-3P
452317-22-5P 452317-24-7P 452317-26-9P
452317-28-1P 452317-30-5P 452317-32-7P
452317-34-9P 452317-36-1P 452317-38-3P
452317-40-7P 452317-42-9P 452317-44-1P
452317-46-3P 452317-48-5P 452317-50-9P
452317-52-1P 452317-54-3P 452317-56-5P
452317-58-7P 452317-60-1P 452317-64-5P
452317-67-8P 452317-69-0P 452317-71-4P
452317-73-6P 452317-76-9P 452317-79-2P
452317-82-7P 452317-84-9P 452317-86-1P
452317-89-4P 452317-92-9P 452317-94-1P
452317-96-3P 452317-99-6P 452318-02-4P
452318-04-6P 452318-07-9P 452318-09-1P
452318-11-5P 452318-13-7P 452318-15-9P
452318-18-2P 452318-20-6P 452318-22-8P
452318-24-0P 452318-27-3P 452318-30-8P
452318-32-0P 452318-34-2P 452318-36-4P
452318-38-6P 452318-41-1P 452318-43-3P
452318-45-5P 452318-47-7P 452318-49-9P
452318-52-4P 452318-54-6P 452318-57-9P
452318-60-4P 452318-63-7P 452318-65-9P
452318-67-1P 452318-69-3P 452318-71-7P
452318-73-9P 452318-75-1P 452318-77-3P
452318-79-5P 452318-81-9P 452318-83-1P
452318-85-3P 452318-87-5P 452318-89-7P
452318-91-1P 452318-93-3P 452318-95-5P
452318-97-7P 452319-00-9P 452319-01-6P
452319-03-8P 452319-05-0P 452319-07-2P
452319-09-4P 452319-11-8P 452319-13-0P
452319-15-2P 452319-17-4P 452319-20-9P
452319-22-1P 452319-24-3P 452319-25-4P
452319-27-6P 452319-29-8P 452319-31-2P
452319-33-4P 452319-35-6P 452319-37-8P
452319-39-0P 452319-41-4P 452319-43-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)
RN 452313-36-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452313-40-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452313-43-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(6-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452313-46-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-50-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452313-54-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-56-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-61-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 5-acetyl-3,3a,4,5-tetrahydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452313-65-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452313-74-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(3-chlorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)



RN 452313-77-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452313-85-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(3-thienyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452313-88-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(4-chlorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452313-91-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methylphenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452313-93-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(3,4-dihydro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452313-98-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(2-pyridinyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452314-01-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452314-05-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenyl-2-butenyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452314-08-8 CAPLUS
CN 1-Piperazineethanamine, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-α-methyl-N-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452314-11-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(3-fluorophenoxy)propyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)



RN 452314-14-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452314-18-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(phenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452314-20-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[[2-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 452314-23-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[[3-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 452314-26-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[[4-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 452314-29-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[[2-(1,1,2,2-tetrafluoroethyl)phenyl]methyl]-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 452314-31-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2-bromophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)



RN 452314-34-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(3-bromophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)



RN 452314-37-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(4-bromophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)



RN 452314-40-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(3-fluorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452314-43-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(4-fluorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452314-46-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2-fluorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452314-49-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(4-nitrophenyl)methyl]-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 452314-52-2 CAPLUS
CN Benzenamine, 4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]-N,N-dimethyl- (CA INDEX NAME)



RN 452314-55-5 CAPLUS
CN Acetamide, N-[4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]phenyl]- (CA INDEX NAME)



RN 452314-57-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2-ethoxyphenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)



RN 452314-60-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(3-phenoxyphenyl)methyl]-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 452314-62-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(4-phenoxyphenyl)methyl]-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 452314-65-7 CAPLUS
CN 1-Propanamine, 3-[4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]phenoxy]-N,N-dimethyl- (CA INDEX NAME)



RN 452314-68-0 CAPLUS
CN Benzoic acid, 4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]-, methyl ester (CA INDEX NAME)



RN 452314-71-5 CAPLUS
CN Benzonitrile, 3-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 452314-74-8 CAPLUS
CN Benzonitrile, 4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 452314-77-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-([1,1'-biphenyl]-3-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452314-80-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2,4-dimethoxyphenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)



RN 452314-83-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(3,4-dimethoxyphenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)



RN 452314-86-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2,4-dichlorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452314-89-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(3,4-dichlorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452314-92-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(4-bromo-2-fluorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452314-95-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(1-methyl-1H-pyrrol-2-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452314-98-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2-phenyl-1H-imidazol-4-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-01-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-thiazolylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-04-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2-phenyl-4-thiazolyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-07-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(2-furanylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-10-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(5-bromo-2-furanyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-13-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(5-methyl-2-furanyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-16-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(3-furanylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-19-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-22-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(5-phenyl-1,3,4-oxadiazol-2-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-24-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-thienylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-27-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(5-bromo-2-thienyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-30-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(4-bromo-2-thienyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-33-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-thienylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-36-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[(3R,5S)-3,5-dimethyl-4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-38-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[(2R,5S)-2,5-dimethyl-4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-40-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[3-methyl-4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-42-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(1-naphthalenylmethyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 452315-44-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(1-naphthalenylmethyl)-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-46-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(1-methoxy-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-48-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(6-methoxy-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-51-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(3-methoxy-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-52-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(7-methyl-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-55-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(6-methyl-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-58-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(3-methyl-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-61-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(7-fluoro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-63-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(6-fluoro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-66-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(5-fluoro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-70-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(5-chloro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-73-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(1-bromo-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-76-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(5-nitro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-79-6 CAPLUS
CN 1-Naphthalenamine, 6-[[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-82-1 CAPLUS
CN 1-Naphthalenamine, 6-[[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]methyl]-N,N-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-85-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(6,7-difluoro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-87-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(5,7-difluoro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-90-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(7,8-difluoro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-92-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(5-bromo-8-methoxy-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-94-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(1H-indol-2-ylmethyl)-1-piperazinyl]methyl]-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-97-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(1H-indol-3-ylmethyl)-1-piperazinyl]methyl]-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-00-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(1H-benzimidazol-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452316-03-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(2-benzofuranylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452316-06-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(benzo[b]thien-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452316-09-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(benzo[b]thien-3-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-12-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-quinolinylmethyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 452316-15-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-18-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(4-quinolinylmethyl)-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452316-21-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-phenylethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-24-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(1,3-benzodioxol-5-yl)ethyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452316-27-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-(2-naphthalenyl)ethyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-30-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-(1-naphthalenyl)ethyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-33-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenylpropyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-36-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(1H-inden-2-ylmethyl)-1-piperazinyl]methyl]-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-39-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(1H-benzimidazol-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-42-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(4-fluorophenoxy)ethyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-45-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(1,3-benzodioxol-5-yloxy)ethyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-48-2 CAPLUS
CN 1H-Inden-1-one, 5-[2-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]ethoxy]-2,3-dihydro-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-51-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-[(2,3-dihydro-5-benzofuranyl)oxy]ethyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-53-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(3-fluorophenoxy)propyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-55-1 CAPLUS
CN 3(2H)-Benzofuranone, 6-[2-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-methylethoxy]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-58-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[[(2R)-6-fluoro-3,4,4a,8a-tetrahydro-2H-1-benzopyran-2-yl]methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-64-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(1,3-benzodioxol-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-66-4 CAPLUS
CN 1-Propanone, 3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-69-7 CAPLUS
CN 1-Piperazinepropanol, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-α-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-72-2 CAPLUS
CN 1-Propanone, 3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-phenyl-, oxime, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452316-75-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452316-81-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenyl-2-propenyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452316-84-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2Z)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452316-87-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452316-89-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-methoxyphenyl)-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452316-91-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(4-methoxyphenyl)-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452316-93-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(4-phenoxyphenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452316-95-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452316-97-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452316-99-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(3-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-02-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452317-04-3 CAPLUS
CN Naphth[1,2-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aS)-rel-(+)-

(9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452317-06-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2-chlorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-08-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(3-chlorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-10-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(4-chlorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-12-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2-bromophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-14-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(3-bromophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-16-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(4-bromophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-18-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-[2-(trifluoromethyl)phenyl]-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-20-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-[3-(trifluoromethyl)phenyl]-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-22-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-[4-(trifluoromethyl)phenyl]-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.



RN 452317-24-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-[2-(1,1,2,2-tetrafluoroethyl)phenyl]-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-26-9 CAPLUS
CN Benzoic acid, 4-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propenyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-28-1 CAPLUS
CN Benzoic acid, 3-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propenyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-30-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-nitrophenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-32-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(2-nitrophenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-34-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-methylphenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-36-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-phenoxyphenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-38-3 CAPLUS
CN Benzonitrile, 2-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-40-7 CAPLUS
CN Benzonitrile, 3-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-42-9 CAPLUS
CN Benzonitrile, 4-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-44-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(3-[1,1'-biphenyl]-2-yl-2-propenyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-46-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(3,4-difluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452317-48-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2,4-difluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452317-50-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2,3-difluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452317-52-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2,6-difluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-54-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2,5-difluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-56-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(3,5-difluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-58-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2,6-dichlorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-60-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2-chloro-4-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452317-64-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2-chloro-6-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-67-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,3-dihydro-1H-inden-5-yl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452317-69-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-71-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(9H-fluoren-2-yl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-73-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2-dibenzofuranyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-76-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(1,3-benzodioxol-5-yl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452317-79-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,3-dihydro-5-benzofuranyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452317-82-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(4,5-dimethoxy-2-nitrophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-84-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-thienyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-86-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-thienyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452317-89-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-thienyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452317-92-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(4-bromo-2-thienyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-94-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(5-bromo-2-thienyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-96-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2-furanyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-99-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-pyridinyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-02-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(2-pyridinyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-04-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-[5-(4-chlorophenyl)-2-furanyl]-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-07-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(2-naphthalenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-09-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(1-naphthalenyl)-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-11-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(4-quinolinyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-13-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(2-quinolinyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-15-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(9-anthracenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)

PAGE 1-A





RN 452318-18-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-1-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-20-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-22-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452318-24-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)-(9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-27-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 452318-26-2
CMF C27 H33 N3 O4

Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 452318-30-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[(2R,5S)-2,5-dimethyl-4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-32-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[(3R,5S)-3,5-dimethyl-4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-34-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[(2R,6S)-2,6-dimethyl-4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-36-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2Z)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-38-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 452318-41-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(2,3-diphenyl-2-propenyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452318-43-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(2-[1,1'-biphenyl]-4-yl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-45-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-(2-naphthalenyl)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-47-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-(phenylmethylene)butyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-49-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-(phenylmethylene)heptyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-52-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-2-bromo-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-54-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-2-chloro-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-57-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-2-fluoro-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-60-4 CAPLUS
CN 1-Piperazinepropanenitrile, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-α-(phenylmethylene)-, (αZ)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-63-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-[4-(1,1-dimethylethyl)phenyl]-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-65-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(3-[1,1'-biphenyl]-4-yl-2-methyl-2-propenyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-67-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-69-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-71-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-73-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-75-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-77-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-79-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-chloro-6-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-81-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-3-(2,5-difluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-83-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,5-difluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-85-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-3-(2,3-difluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-87-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,3-difluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-89-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-methyl-3-(1-naphthalenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-91-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(2H-1-benzopyran-3-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452318-93-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-95-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-97-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-99-9 CAPLUS
CN Phenol, 3-[(1E)-3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-methyl-1-propenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-01-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-thienyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-03-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(2-thienyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-05-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,5-dimethyl-3-thienyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-07-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-furanyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-09-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(3-pyridinyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-11-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(2-methyl-4-thiazolyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-13-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2-phenyl-1-cyclopenten-1-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452319-15-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenyl-2-propynyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452319-17-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]propyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452319-20-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(4-fluorophenoxy)propyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452319-22-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-4-(2-fluorophenyl)-2-methyl-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-24-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E,4E)-5-phenyl-2,4-pentadienyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-25-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-27-6 CAPLUS
CN Benzoic acid, 4-[(1E)-3-[4-[[(3R,3aS)-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propenyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-29-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-fluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-31-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-33-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-35-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-37-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



●2 HCl

RN 452319-39-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



●2 HCl

RN 452319-41-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-43-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-(2-methoxyethoxy)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 452319-45-8P 452319-47-0P 452319-49-2P
452319-51-6P 452319-53-8P 452319-55-0P
452319-57-2P 452319-59-4P 452319-61-8P
452319-63-0P 452319-65-2P 452319-67-4P
452319-69-6P 452319-71-0P 452319-73-2P
452319-75-4P 452319-77-6P 452319-78-7P
452319-80-1P 452319-81-2P 452319-83-4P
452319-85-6P 452319-87-8P 452319-89-0P
452319-91-4P 452319-93-6P 452319-95-8P
452319-97-0P 452319-99-2P 452320-01-3P
452320-03-5P 452320-06-8P 452320-07-9P
452320-09-1P 452320-11-5P 452320-13-7P
452320-15-9P 452320-17-1P 452320-19-3P
452320-21-7P 452320-23-9P 452320-25-1P
452320-27-3P 452320-29-5P 452320-31-9P
452320-34-2P 452320-36-4P 452320-38-6P
452320-40-0P 452320-42-2P 452320-44-4P
452320-46-6P 452320-48-8P 452320-50-2P
452320-52-4P 452320-54-6P 452320-56-8P
452320-58-0P 452320-60-4P 452320-62-6P
452320-64-8P 452320-66-0P 452320-68-2P
452320-70-6P 452320-72-8P 452320-74-0P
452320-76-2P 452320-78-4P 452320-80-8P
452320-82-0P 452320-84-2P 452320-86-4P
452320-88-6P 452320-90-0P 452320-92-2P
452320-94-4P 452320-96-6P 452320-98-8P
452321-00-5P 452321-02-7P 452321-04-9P
452321-06-1P 452321-08-3P 452321-10-7P
452321-12-9P 452321-14-1P 452321-16-3P
452321-19-6P 452321-21-0P 452321-23-2P
452321-25-4P 452321-27-6P 452321-29-8P
452321-31-2P 452321-33-4P 452321-35-6P
452321-37-8P 452321-39-0P 452321-41-4P
452321-43-6P 452321-45-8P 452321-47-0P
452321-49-2P 452321-51-6P 452321-53-8P
452321-55-0P 452321-61-8P 452934-93-9P
452934-94-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)

RN 452319-45-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-[(2-methoxyethoxy)methoxy]-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-47-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-[(2-methoxyethoxy)methoxy]-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-49-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-[(2-methoxyethoxy)methoxy]-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-51-6 CAPLUS
CN Carbamic acid, ethyl-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl

ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-53-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-55-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-57-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, propanoate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-59-4 CAPLUS
CN Acetic acid, methoxy-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-61-8 CAPLUS
CN Cyclopropanecarboxylic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-63-0 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-65-2 CAPLUS
CN 2-Propenoic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-67-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(cyclopentyloxy)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-69-6 CAPLUS
CN 4-Pyridinecarboxylic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-71-0 CAPLUS
CN Ethanamine, 2-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]-N,N-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-73-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, hydrogen sulfite (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-75-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-chloro-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-77-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-chloro-3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-78-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-bromo-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-80-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-bromo-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452319-81-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-bromo-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452319-83-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7,8-difluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-85-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-fluoro-3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-87-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-phenyl-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-89-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methyl-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-91-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-fluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-(methylthio)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-93-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7,8-diol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452319-95-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-8-ol, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-97-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-8-ol, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-99-2 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-8-yl]oxy]-, acetate (ester), rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-01-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-03-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-06-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-07-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-09-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(cyclopropylmethoxy)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-11-5 CAPLUS
CN Cyclopropanecarboxylic acid, (3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-13-7 CAPLUS
CN 3-Pyridinecarboxylic acid, (3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-15-9 CAPLUS
CN Carbamic acid, ethyl-, (3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-17-1 CAPLUS
CN Ethanamine, 2-[[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]-N,N-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-19-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-7-[(2-methoxyethoxy)methoxy]-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-21-7 CAPLUS
CN Carbonic acid, (3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-23-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-(2-propenyloxy)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-25-1 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-27-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, methanesulfonate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-29-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-31-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-phenyl-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-34-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-(methylthio)-, (3R,3aS)-rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 452320-33-1

CMF C27 H33 N3 O3 S

Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 452320-36-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-38-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-40-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-42-2 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-44-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452320-46-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452320-48-8 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-50-2 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-52-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-5-methyl-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-54-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-5-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-56-8 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-5-(phenylmethyl)-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-58-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-5-(trifluoroacetyl)-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-60-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-5-(trifluoroacetyl)-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-62-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 5-acetyl-3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-64-8 CAPLUS
CN Isoxazolo[4,3-c]quinoline-5(3H)-carboxylic acid, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, ethyl ester, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-66-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline-5(3H)-carboxamide, N-ethyl-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-68-2 CAPLUS
CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452320-70-6 CAPLUS
CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-72-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(phenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452320-74-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(3-phenylpropyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

RN 452320-76-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452320-78-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-[(2-methoxyethoxy)methoxy]-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



PAGE 1-A

PAGE 1-B

—OMe

RN 452320-80-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452320-82-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(cyclopropylmethoxy)-3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452320-84-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(difluoromethoxy)-3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452320-86-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-7-[(tetrahydro-3-furanyl)oxy]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452320-88-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452320-90-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-8-methoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452320-92-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-94-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-fluorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-96-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-98-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-00-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(4-methoxyphenyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-02-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-[3-(trifluoromethyl)phenyl]-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-04-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-[4-(trifluoromethyl)phenyl]-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-06-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-chlorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-08-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-chlorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-10-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-chlorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-12-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(4-methylphenyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-14-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-16-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-methoxyphenyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-19-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-3-fluoro-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-21-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,4-difluorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-23-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3,4-difluorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-25-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-pyridinyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-27-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-pyridinyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-29-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-thienyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-31-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-furanyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-33-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(4-chlorophenyl)methyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452321-35-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[2-(4-fluorophenoxy)ethyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452321-37-8 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-39-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452321-41-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(6-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452321-43-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(5-fluoro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452321-45-8 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[2-(2-naphthalenyloxy)ethyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452321-47-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-5-methyl-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452321-49-2 CAPLUS
CN [1,3]Dioxolo[6,7]naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452321-51-6 CAPLUS
CN [1,3]Dioxolo[6,7]naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452321-53-8 CAPLUS
CN Furo[2',3':6,7]naphth[1,2-c]isoxazole, 3,3a,4,5,8,9-hexahydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-55-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[2-[4-(2-naphthalenylmethyl)-1-piperazinyl]ethyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452321-61-8 CAPLUS
CN 1-Piperazinemethanamine, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-N-2-naphthalenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452934-93-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(7-fluoro-2,3,4a,8a-tetrahydro-1,4-dioxino[2,3-b]pyridin-3-yl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452934-94-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(6-fluoro-3,4,4a,8a-tetrahydro-4-methyl-2H-1,4-benzoxazin-2-yl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

STRUCTURE SEARCH

```
=> fil reg; d stat que l12
FILE 'REGISTRY' ENTERED AT 12:24:29 ON 14 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   13 JAN 2008  HIGHEST RN 960495-31-2
DICTIONARY FILE UPDATES:  13 JAN 2008  HIGHEST RN 960495-31-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html
```

L9 STR




```
VAR G1=16/22/41
VAR G2=CH2/N/S/O
REP G3=(1-4) CH2
REP G4=(1-6) 44
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  35 39 43 44
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  44
```

```
STEREO ATTRIBUTES: NONE
L12          614 SEA FILE=REGISTRY SSS FUL L9

100.0% PROCESSED     937 ITERATIONS                          614 ANSWERS
SEARCH TIME: 00.00.01



=> d que nos l20
L9                STR
L12           614 SEA FILE=REGISTRY SSS FUL L9
L20            33 SEA FILE=REGISTRY ABB=ON  L12 NOT CAPLUS/LC
      THESE 33 COMPOUNDS DO NOT HAVE REFERENCES.  THEY ONLY HAVE REGISTRY RECORDS.
THE ED FIELD SHOWS THE DATE OF PUBLIC AVAILABILITY FOR THE REGISTRY RECORD.

=> d ide l20

L20  ANSWER 1 OF 33  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   792906-02-6  REGISTRY
ED   Entered STN:  06 Dec 2004
CN   3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanol, 3a,4-dihydro-8-methoxy-3-[[4-
     [(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-
     (9CI)  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C27 H33 N3 O4
CI   COM
SR   CA

Relative stereochemistry.
Double bond geometry as shown.
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**



=> d ide l20 2-33

L20  ANSWER 2 OF 33  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   792181-47-6  REGISTRY
ED   Entered STN:  05 Dec 2004
CN   3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(4-fluorophenoxy)ethyl]-1-
     piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-  (CA INDEX
     NAME)
FS   STEREOSEARCH
MF   C25 H30 F N3 O5
CI   COM
SR   CA
```

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 3 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 791061-56-8 REGISTRY
ED Entered STN: 01 Dec 2004
CN Ethanol, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methyl]methylamino]-, rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H38 N4 O3
CI COM
SR CA

Relative stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 4 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 784138-61-0 REGISTRY
ED Entered STN: 19 Nov 2004
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-(methoxymethyl)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H33 N3 O3
CI COM
SR CA

Relative stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 5 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 782443-81-6 REGISTRY
ED Entered STN: 16 Nov 2004
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(4-methoxyphenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H33 N3 O5
CI COM
SR CA

Relative stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 6 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 776288-62-1 REGISTRY
ED Entered STN: 08 Nov 2004
CN [1,3]Dioxolo[6,7]naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H29 N3 O3
CI COM
SR CA

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 7 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 775278-99-4 REGISTRY
ED Entered STN: 05 Nov 2004
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(1,3-benzodioxol-5-yl)ethyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H31 N3 O6
CI COM
SR CA

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 8 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 771473-65-5 REGISTRY
ED Entered STN: 28 Oct 2004
CN 1,2-Ethanediamine, N,N-diethyl-N'-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-methyl-, rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H44 F N5 O2
CI COM
SR CA

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

—NEt$_2$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 9 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 771469-76-2 REGISTRY
ED Entered STN: 28 Oct 2004
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H29 N3 O3
CI COM
SR CA

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 10 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 768354-12-7 REGISTRY
ED Entered STN: 25 Oct 2004
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H29 N3 O3
CI COM

SR CA

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 11 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 767281-23-2 REGISTRY
ED Entered STN: 22 Oct 2004
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-(1-naphthalenyl)ethyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H33 N3 O4
CI COM
SR CA

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 12 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 763077-36-7 REGISTRY
ED Entered STN: 15 Oct 2004
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7,8-diol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H29 N3 O4
CI COM
SR CA

Relative stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 13 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 761394-91-6 REGISTRY
ED Entered STN: 13 Oct 2004
CN Phosphonium, [2-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]ethyl]triphenyl-, rel- (CA INDEX NAME)
FS STEREOSEARCH
MF C37 H41 N3 O4 P
CI COM
SR CA

Relative stereochemistry.



L20 ANSWER 14 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 760171-48-0 REGISTRY
ED Entered STN: 11 Oct 2004
CN 1,2-Ethanediamine, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-methyl-, rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H36 F N5 O2
CI COM
SR CA

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

NHMe

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 15 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 756470-52-7 REGISTRY
ED Entered STN: 04 Oct 2004
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H29 N3 O3
CI COM
SR CA

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 16 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 753443-75-3 REGISTRY
ED Entered STN: 29 Sep 2004
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-methoxyphenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H33 N3 O5
CI COM
SR CA

Relative stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 17 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 752196-48-8 REGISTRY
ED Entered STN: 27 Sep 2004
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-(2-naphthalenyl)ethyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H33 N3 O4
CI COM
SR CA

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 18 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 751478-71-4 REGISTRY
ED Entered STN: 26 Sep 2004
CN 1,2-Ethanediamine, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N-methyl-, rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H36 F N5 O2
CI COM
SR CA

Relative stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 19 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 748767-44-4 REGISTRY
ED Entered STN: 21 Sep 2004
CN 1,2-Ethanediamine, N-[(3R,3aS)-3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N,N',N'-trimethyl-, rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H40 F N5 O2
CI COM
SR CA

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

—NMe2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 20 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 746603-79-2 REGISTRY
ED Entered STN: 17 Sep 2004
CN 1,2-Ethanediamine, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-

propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N,N',N'-trimethyl-, rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H40 F N5 O2
CI COM
SR CA

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

—NMe2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 21 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 742690-14-8 REGISTRY
ED Entered STN: 12 Sep 2004
CN Ethanol, 2-[[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]-, rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H35 N3 O5
CI COM
SR CA

Relative stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 22 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 740078-04-0 REGISTRY
ED Entered STN: 06 Sep 2004
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(1-naphthalenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H33 N3 O4
CI COM
SR CA

Relative stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 23 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 739359-45-6 REGISTRY
ED Entered STN: 05 Sep 2004
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(2-benzofuranylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H29 N3 O5
CI COM
SR CA

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 24 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 737750-39-9 REGISTRY
ED Entered STN: 02 Sep 2004
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-3-fluoro-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H30 F N3 O4
CI COM
SR CA

Relative stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 25 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 734528-01-9 REGISTRY
ED Entered STN: 27 Aug 2004
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(4-fluorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)
FS STEREOSEARCH
MF C24 H28 F N3 O4
CI COM
SR CA

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 26 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 692257-06-0 REGISTRY
ED Entered STN: 11 Jun 2004
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(4-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H30 N4 O4
CI COM
SR CA

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 27 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 687633-36-9 REGISTRY
ED Entered STN: 31 May 2004
CN [1,3]Dioxolo[6,7]naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H29 N3 O3
CI COM
SR CA

Relative stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 28 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 682329-62-0 REGISTRY
ED Entered STN: 16 May 2004
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-

3-(2-methoxyphenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-
(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H33 N3 O5
CI COM
SR CA

Relative stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 29 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 663933-75-3 REGISTRY
ED Entered STN: 17 Mar 2004
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxamide, N-ethyl-3a,4-dihydro-8-
methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-,
(3R,3aS)-rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H36 N4 O4
CI COM
SR CA

Relative stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 30 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 663933-73-1 REGISTRY
ED Entered STN: 17 Mar 2004
CN Acetamide, N-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-
propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-

yl]methyl]-, rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H34 N4 O3
CI COM
SR CA

Relative stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 31 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 663933-67-3 REGISTRY
ED Entered STN: 17 Mar 2004
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-(phenoxymethyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C33 H37 N3 O4
CI COM
SR CA

Relative stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 32 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 663933-64-0 REGISTRY
ED Entered STN: 17 Mar 2004
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-7-[[(2-methoxyethoxy)methoxy]methyl]-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H41 N3 O6

CI COM
SR CA

Relative stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 ANSWER 33 OF 33 REGISTRY COPYRIGHT 2008 ACS on STN
RN 452320-33-1 REGISTRY
ED Entered STN: 18 Sep 2002
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-(methylthio)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H33 N3 O3 S
CI COM
SR CA

Relative stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

REFERENCES FOR COMPOUNDS FROM REGISTRY SEARCH

```
=> fil capl; d que nos l13
FILE 'CAPLUS' ENTERED AT 12:24:59 ON 14 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 14 Jan 2008  VOL 148 ISS 3
FILE LAST UPDATED: 13 Jan 2008  (20080113/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE


L9              STR
L12          614 SEA FILE=REGISTRY SSS FUL L9
L13           12 SEA FILE=CAPLUS ABB=ON  L12


=> s l13 not l19
L21           2 L13 NOT L19     L19 ANSWERS PRINTED WITH INVENTOR SEARCH

=> d ibib abs hitstr l21 1-2

L21  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2004:760314  CAPLUS  Full-text
DOCUMENT NUMBER:          141:384410
TITLE:                    A screening strategy for the development of
                          enantiomeric separation methods in capillary
                          electrophoresis
AUTHOR(S):                Jimidar, M. Ilias; van Ael, Willy; van Nyen, Patrick;
                          Peeters, Margot; Redlich, Dirk; de Smet, Maurits
CORPORATE SOURCE:         Pharmaceutical Research & Development (J&J-PRD) A
                          division of Janssen Pharmaceutica n.v., Global
                          Analytical Development, Johnson and Johnson, Beerse,
                          Belg.
SOURCE:                   Electrophoresis (2004), 25(16), 2772-2785
                          CODEN: ELCTDN; ISSN: 0173-0835
PUBLISHER:                Wiley-VCH Verlag GmbH & Co. KGaA
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
AB    Method development of enantiomeric sepns. in capillary electrophoresis (CE) is
      a time-consuming task, since finding the appropriate chiral selector is
      usually a "trial and error" process.  It is impossible to predict the
      selectivity of a selector towards a certain enantiomer. Therefore, the
```

affinity of all selectors has to be examined one at a time. In order to speed up this process, a strategy is proposed based on simple exptl. design methodol. The approach includes first a screening in function of the pH to determine the optimal migration conditions followed by a selection of the right chiral selector by means of Taguchi designs. In the approach several variables, such as the type and concentration of cyclodextrin, the concentration of buffer electrolyte, and the percentage of organic modifier, are varied simultaneously to find initial separation conditions rapidly. The resulting initial separation conditions can be optimized in further steps to be more reproducible. We discuss the results of the approach when applied on a number of selected compds. that are recently in development at Johnson & Johnson - Pharmaceutical Research and Development. Parameters, such as quality of the separation and anal. time, are evaluated to determine initial separation conditions for each compound

IT 452318-73-9
RL: ANT (Analyte); ANST (Analytical study)
(screening strategy for development of enantiomeric separation methods in capillary electrophoresis)

RN 452318-73-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:892834 CAPLUS Full-text
DOCUMENT NUMBER: 139:365764
TITLE: Diblock copolymers for use in pharmaceutical dosage forms
INVENTOR(S): Arieen, Albertina Maria Eduarda; Brewster, Marcus Eli; Nathan, Aruna; Rosenblatt, Joel; Ould-Ouali, Louisa Myriam; Preat, Veronique
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093344	A1	20031113	WO 2003-EP4368	20030424

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA	2483282	A1	20031113	CA 2003-2483282	20030424
AU	2003222310	A1	20031117	AU 2003-222310	20030424
EP	1504047	A1	20050209	EP 2003-717321	20030424
EP	1504047	B1	20071212		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR	2003009688	A	20050222	BR 2003-9688	20030424
NZ	536294	A	20050527	NZ 2003-536294	20030424
CN	1649932	A	20050803	CN 2003-809579	20030424
JP	2005524730	T	20050818	JP 2004-501483	20030424
AT	380834	T	20071215	AT 2003-717321	20030424
MX	2004PA10778	A	20050307	MX 2004-PA10778	20041029
ZA	2004008854	A	20051102	ZA 2004-8854	20041102
NO	2004005283	A	20050107	NO 2004-5283	20041202
US	20060034797	A1	20060216	US 2005-522456	20050121

PRIORITY APPLN. INFO.: US 2002-377901P P 20020503
WO 2003-EP4368 W 20030424

AB In a diblock copolymer of formula A-B, polymer block A represents a linear pharmaceutically acceptable hydrophilic polymer and polymer block B represents a polymer comprising monomers selected from L-lactic acid, D-lactic acid, D,L-lactic acid, glycolic acid, propiolactone, γ-butyrolactone, δ-valerolactone, γ-valerolactone, ε-caprolactone, trimethylene carbonate, p-dioxanone, tetramethylene carbonate, ε-lactone, 1,5-dioxepan-2-one or mixts. thereof characterized in that the diblock copolymer is liquid at a temperature below 50°. A polymer was prepared from ε-caprolactone, trimethylene carbonate, and polyethylene glycol monomethyl ether initiator.

IT 452314-01-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diblock copolymers for use in pharmaceutical dosage forms)

RN 452314-01-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> fil marpat
FILE 'MARPAT' ENTERED AT 12:25:39 ON 14 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 148 ISS 2 (20080111/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US   2007276042 29 NOV 2007
DE 202007010952 22 NOV 2007
EP      1860709 28 NOV 2007
JP   2007318072 06 DEC 2007
WO   2007137513 06 DEC 2007
GB      2438402 28 NOV 2007
FR      2901275 23 NOV 2007
RU      2311402 27 NOV 2007
CA      2584745 13 OCT 2007

Expanded G-group definition display now available.

Effective December 15th the iteration and answer limits in MARPAT
have increased from 100,000 to 200,000 for both on-line and batch
searches.  For more information on MARPAT search limits, type HELP
SLIMITS at an arrow prompt.

=> S L12

'EXTEND' DOES NOT APPLY TO SAMPLE SEARCHES

STRUCTURE TOO LARGE - SEARCH ENDED
```

SEARCH HISTORY

```
=> fil home
FILE 'HOME' ENTERED AT 12:25:49 ON 14 JAN 2008

=> d stat que l12; d his nofile
L9              STR
```










```
VAR G1=16/22/41
VAR G2=CH2/N/S/O
REP G3=(1-4) CH2
REP G4=(1-6) 44
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  35 39 43 44
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  44

STEREO ATTRIBUTES: NONE
L12         614 SEA FILE=REGISTRY SSS FUL L9

100.0% PROCESSED     937 ITERATIONS                          614 ANSWERS
SEARCH TIME: 00.00.01




     (FILE 'HOME' ENTERED AT 12:11:51 ON 14 JAN 2008)

     FILE 'CAPLUS' ENTERED AT 12:12:03 ON 14 JAN 2008
                E US2005-524989/APPS
L1             1 SEA ABB=ON  US2005-524989/AP
                D SCAN
                SEL RN

     FILE 'REGISTRY' ENTERED AT 12:12:38 ON 14 JAN 2008
L2            31 SEA ABB=ON  (105-58-8/BI OR 109-01-3/BI OR 1117-71-1/BI OR
                14382-91-3/BI OR 148-53-8/BI OR 152960-43-5/BI OR 184687-49-8/B
                I OR 452321-63-0/BI OR 452321-65-2/BI OR 452321-67-4/BI OR
                452321-69-6/BI OR 452321-71-0/BI OR 504-24-5/BI OR 667454-35-5/
```

```
                BI OR 667454-36-6/BI OR 667454-37-7/BI OR 667454-38-8/BI OR
                667454-39-9/BI OR 667454-40-2/BI OR 667454-41-3/BI OR 667454-42
                -4/BI OR 667454-43-5/BI OR 667454-44-6/BI OR 667454-45-7/BI OR
                667454-46-8/BI OR 667454-47-9/BI OR 667454-48-0/BI OR 667454-49
                -1/BI OR 667454-50-4/BI OR 667454-51-5/BI OR 667454-52-6/BI)
                D SCAN
L3              STR
L4           27 SEA SSS SAM L3
L5            1 SEA ABB=ON  L4 AND L2

     FILE 'ZCAPLUS' ENTERED AT 12:17:22 ON 14 JAN 2008
L6           10 SEA ABB=ON  L4

     FILE 'REGISTRY' ENTERED AT 12:17:39 ON 14 JAN 2008
L7              STR L3
L8           27 SEA SSS SAM L7
L9              STR L7
L10          27 SEA SSS SAM L9
L11         937 SEA SSS FUL L9 EXTEND
L12         614 SEA SSS FUL L9
                SAVE TEMP L12 SHT989FULL/A

     FILE 'CAPLUS' ENTERED AT 12:20:01 ON 14 JAN 2008
L13          12 SEA ABB=ON  L12
L14        1263 SEA ABB=ON  ANDRES GIL J?/AU OR ANDRES J?/AU OR GIL J?/AU
L15          52 SEA ABB=ON  ALCAZAR VACA M?/AU OR ALCAZAR M?/AU OR VACA M?/AU
L16         152 SEA ABB=ON  MATESANZ BALLESTEROS M?/AU OR MATESANZ M?/AU OR
                BALLESTEROS M?/AU
L17         258 SEA ABB=ON  BAKKER M?/AU
L18          85 SEA ABB=ON  MEGENS A?/AU
L19          10 SEA ABB=ON  (L1 OR L14 OR L15 OR L16 OR L17 OR L18) AND L13

     FILE 'REGISTRY' ENTERED AT 12:22:10 ON 14 JAN 2008
L20          33 SEA ABB=ON  L12 NOT CAPLUS/LC

     FILE 'MARPAT' ENTERED AT 12:23:02 ON 14 JAN 2008

     FILE 'CAPLUS' ENTERED AT 12:23:45 ON 14 JAN 2008
                D QUE NOS L19
                D IBIB ABS HITSTR L19 1-10

     FILE 'REGISTRY' ENTERED AT 12:24:29 ON 14 JAN 2008
                D STAT QUE L12
                D QUE NOS L20
                D IDE L20
                D IDE L20 2-33

     FILE 'CAPLUS' ENTERED AT 12:24:59 ON 14 JAN 2008
                D QUE NOS L13
L21           2 SEA ABB=ON  L13 NOT L19
                D IBIB ABS HITSTR L21 1-2

     FILE 'MARPAT' ENTERED AT 12:25:39 ON 14 JAN 2008

     FILE 'HOME' ENTERED AT 12:25:49 ON 14 JAN 2008
                D STAT QUE L12

=>
```